{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:57:13Z","timestamp":1791219433540,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The purpose of this meta-analysis is to evaluate the safety and effectiveness of intrathecal pemetrexed (IP) in patients with non-small cell lung cancer with leptomeningeal metastasis (NSCLC-LM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of PubMed, the Cochrane library, Embase, and ClinicalTrials.gov databases was executed until December 11, 2024. The quality of the selected studies was evaluated using the Risk Of Bias In Non-randomized Studies Of Interventions (ROBINS-I) tool. Data extracted encompassed disease control rate (DCR), objective response rate (ORR), median overall survival (mOS), and adverse events (AEs). A random-effects model was used in the meta-analysis, which was conducted using STATA 15.1 software. Egger\u2019s and Begg\u2019s tests were used to analyze publication bias, and when significant publication bias was detected, the Trim and Fill method was employed to adjust for the bias.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis included 8 studies involving a total of 306 patients, with a pooled ORR of 57.6% (95% CI: 39.5%-74.7%). Further subgroup analysis revealed that a pemetrexed dosage of 40\u201350 mg exhibited superior efficacy, with an ORR of 84.5% (95% CI: 70.0%-95.6%), compared to an ORR of 46.6% (95% CI: 29.2%-64.4%) for dosages of 10\u201330 mg. Additionally, patients with EGFR mutations exhibited an ORR of 56.2% (95% CI: 34.7%-76.6%), while those with other genetic subtypes had an ORR of 44.8% (95% CI: 25.1%-65.1%). The combined DCR was 85.4% (95% CI: 76.5%-92.7). In terms of survival, the pooled data from 6 studies yielded a mOS of 8.12 months (95% CI: 6.07-10.17). Common adverse events associated with pemetrexed included myelosuppression (32.6%), headache (24.8%), abnormal transaminase (11.8%), nausea (7.3%), vomiting (11.7%), radiculitis (8.4%) and leukoencephalopathy (6.4%). Potential publication bias was identified for DCR and grade\u2265III myelosuppression. Subgroup analyses performed by DCR showed that the bias was related to drug dosage, while the Trim and Fill method for grade \u2265III myelosuppression did not reverse the bias. These findings suggest that publication bias had minimal impact and that the results were relatively stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This meta-analysis concludes that patients with NSCLC-LM benefit from intrathecal chemotherapy using pemetrexed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1543416","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T02:12:38Z","timestamp":1750212758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Yushi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70443-4","article-title":"Neoplastic meningitis","volume":"5","author":"Gleissner","year":"2006","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0119","article-title":"Leptomeningeal carcinomatosis","volume":"25","author":"Grossman","year":"1999","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2015.04.003","article-title":"Survival following Ommaya reservoir placement for neoplastic meningitis","volume":"22","author":"Roguski","year":"2015","journal-title":"J Clin Neurosci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.jns.2020.116706","article-title":"Leptomeningeal metastasis from solid tumors","volume":"411","author":"Thakkar","year":"2020","journal-title":"J Neurol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03924-2","article-title":"Leptomeningeal metastases: the future is now","volume":"156","author":"Lukas","year":"2022","journal-title":"J Neurooncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment","volume":"174","author":"Wang","year":"2022","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2165\/11202640-000000000-00000","article-title":"Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-018-0802-x","article-title":"Fixed and random effects models: making an informed choice","volume":"53","author":"Bell","year":"2019","journal-title":"Qual Quantity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00838","article-title":"A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer","volume":"9","author":"Pan","year":"2019","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-2086","article-title":"Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis","volume":"9","author":"Miao","year":"2020","journal-title":"Ann Palliat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1758835920937953","DOI":"10.1177\/1758835920937953","article-title":"Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I\/II study","volume":"12","author":"Pan","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1\/2 clinical trial (Unique identifier: chiCTR1800016615)","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15330338221078429","DOI":"10.1177\/15330338221078429","article-title":"A retrospective study of intrathecal pemetrexed combined with systemic therapy for leptomeningeal metastasis of lung cancer","volume":"21","author":"Geng","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/j.cllc.2022.11.011","article-title":"Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective phase I study","volume":"24","author":"Li","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12885-023-10806-5","article-title":"Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology","volume":"23","author":"J\u00e4nne","year":"2005","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.019","article-title":"Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"116","author":"Hendriks","year":"2019","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): A nonrandomized, phase II study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4783","article-title":"Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis","volume":"12","author":"Wu","year":"2016","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ctrv.2015.12.004","article-title":"Therapy of leptomeningeal metastasis in solid tumors","volume":"43","author":"Mack","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110","article-title":"Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis","volume":"17","author":"Glantz","year":"1999","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.3389\/fonc.2025.1660077","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1543416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T15:47:49Z","timestamp":1753285669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1543416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1543416"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1543416","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fonc.2025.1660077","asserted-by":"object"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"article-number":"1543416"}}